Sherbrooke Park Advisers LLC Makes New Investment in Amedisys, Inc. (NASDAQ:AMED)

Sherbrooke Park Advisers LLC acquired a new position in Amedisys, Inc. (NASDAQ:AMED) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,185 shares of the health services provider’s stock, valued at approximately $380,000.

Other large investors have also recently bought and sold shares of the company. Trexquant Investment LP raised its position in Amedisys by 1,317.8% in the fourth quarter. Trexquant Investment LP now owns 87,719 shares of the health services provider’s stock worth $7,964,000 after acquiring an additional 81,532 shares in the last quarter. ABC Arbitrage SA purchased a new position in Amedisys in the fourth quarter worth $2,522,000. Schonfeld Strategic Advisors LLC raised its position in Amedisys by 17.5% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 4,500 shares of the health services provider’s stock worth $409,000 after acquiring an additional 671 shares in the last quarter. Empowered Funds LLC purchased a new position in Amedisys in the fourth quarter worth $318,000. Finally, KLP Kapitalforvaltning AS purchased a new position in Amedisys in the fourth quarter worth $590,000. Hedge funds and other institutional investors own 94.36% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Stephens reiterated an “equal weight” rating and issued a $101.00 price objective on shares of Amedisys in a research report on Tuesday, March 4th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $100.00 price target on shares of Amedisys in a research note on Wednesday, April 16th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat.com, Amedisys presently has an average rating of “Hold” and an average target price of $100.75.

Amedisys Trading Up 1.0%

NASDAQ:AMED opened at $94.62 on Friday. The company has a market capitalization of $3.11 billion, a PE ratio of 37.55, a price-to-earnings-growth ratio of 1.78 and a beta of 0.96. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05. Amedisys, Inc. has a 52-week low of $82.15 and a 52-week high of $98.95. The stock has a fifty day simple moving average of $93.22 and a 200-day simple moving average of $91.63.

Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.12. The business had revenue of $594.78 million during the quarter, compared to the consensus estimate of $597.43 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The business’s revenue was up 4.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.03 EPS. On average, equities research analysts expect that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.